The association of −330 interleukin‐2 gene polymorphism and HLA‐DR15 allele in Iranian patients with multiple sclerosis

This study indicated that the −330 T IL2 allele and the T/T genotype were related to increased plasma concentration of IL2 and a higher risk of developing MS among Iranian patients. Carrying both the −330 T IL2 and the HLA, DRB1* 1501 alleles showed the most susceptibly effect to MS. Our data demonstrated −330 T IL2 allele provided major susceptibility to MS and HLA‐DRB1* 1501 allele had an additive effect. In addition, it seems that studies with larger sample size are required to bring about more authentic results. Our findings suggest that IL2 gene polymorphisms influence the susceptibility to MS in Iranian patients.
Source: International Journal of Immunogenetics - Category: Genetics & Stem Cells Authors: Tags: Original Article Source Type: research

Related Links:

ConclusionMS patients with a higher disability at TN onset and with a longer interval between MS and TN onset had differing clinical features and outcomes: pain was more frequently bilateral, surgery was more frequent and anticipated, and preventive medication discontinuation due to pain remission was less common.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
We report the case of a 9-year-old girl with linear scleroderma en coup de sabre (LSCS) who developed progressive white matter involvement, presenting as intractable hemiplegic migraine-like attacks induced by exercise. After a period of severely aggressive course, clinical and radiological stabilization was achieved under immunosuppressant treatment. Intrathecal synthesis of IgG and lymphocytic pleocytosis provided indirect evidence of a chronic inflammatory process of the central nervous system. We discuss the possible immunopathogenic mechanisms responsible for the neurocutaneous involvement in LSCS, favouring the hypot...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 18 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Luis Andreu, Domingo J. Ramos-Campo, Vicente Ávila-Gandía, Tomas Freitas, Linda H. Chung, Jacobo Á. Rubio-AriasAbstractBackgroundWhole-body vibration training (WBVT) has been used in people with relapsing-remitting multiple sclerosis (pwMS), showing improvements in different neuromuscular and mobility variables. However, the acute effects of this training are still unknown. The acute effects of WBVT on neuromuscular performance, mobility and rating of perceived exertion (RPE) were evaluated in 1...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionsFP clinically classified as peripheral may be caused by central lesions in the cortex or pons and not only by peripheral facial nerve damage. In MS patients, FP may appear at the onset of the disease and be misdiagnosed as Bell ’s palsy. Clinicians should carefully approach FP diagnosis and perform a brain as well as temporal bone MRI before pursuing pharmacological treatment.Graphical Abstract
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 18 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Lisbet Marstrand, Ole Østerberg, Trine Walsted, Amalie C. Skov, Karen I. Schreiber, Finn SellebjergAbstractBackgroundCognitive impairment is highly prevalent in multiple sclerosis (MS). Due to the lack of specialized neuropsychological resources in many MS clinics, a brief cognitive monitoring tool that can be administered by other MS clinic staff is needed. BICAMS (Brief International Cognitive As-sessment for Multiple Sclerosis) has been developed and recommended by MS experts to monitor MS-related cognitiv...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 18 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): B. Yamout, M. Sahraian, S. Bohlega, M. Al-Jumah, R. Goueider, M. Dahdaleh, J. Inshasi, S. Hashem, I. Alsharoqi, S. Khoury, M Alkhawajah, Riyadh S. Koussa, J. Al Khaburi, A. Almahdawi, T. Alsaadi, E. Slassi, S Daodi, M. Zakaria, R. AlroughaniAbstractWith evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS, most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
.
Source: Aphasiology - Category: Speech-Language Pathology Authors: Source Type: research
AbstractMultiple sclerosis (MS) is treated with a variety of immunomodulatory and immunosuppressive drugs. Among the most potent therapeutic options are monoclonal antibodies (MAbs). So far, the MAbs natalizumab, alemtuzumab, and ocrelizumab have been approved for MS treatment. While their efficacy is indisputable, these drugs have safety issues not seen with previous MS drugs. MAbs are the ideal class of treatment for many patients with MS, but neurologists prescribing these MAbs need to be aware of their potential risks and monitor patients closely. Although rare, adverse events associated with MAbs may be fatal; opportu...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 18 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Jeannette Lechner-Scott, Emmanuelle Waubant, Michael Levy, Christopher Hawkes
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 16 October 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Edgar Carnero C, Pablo A. López, Juan Pablo Pettinicchi, Ricardo Alonso, Santiago Tizio, Verónica Tkachuk, Alejandro Caride, Ian GaleaAbstractBackgroundDemographics, clinical and imaging prognostic factors have been reported in large series of people with multiple sclerosis (PwMS). However, personalized long-term prognosis (LTP) is varied and uncertain in each particular case. Currently, there is limited evidence on how PwMS feel about prognosis communication and their coping strategies. Therefore, we ...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Genetics | Hospitals | Multiple Sclerosis | Study | Women